Elizabeth C Reuman

Summary

Affiliation: Stanford University
Country: USA

Publications

  1. ncbi Panel of prototypical raltegravir-resistant infectious molecular clones in a novel integrase-deleted cloning vector
    Elizabeth C Reuman
    Department of Medicine, Stanford University School of Medicine, Division of Infectious Diseases, 300 Pasteur Drive, Grant Building, Room S 146, Stanford, CA 94305, USA
    Antimicrob Agents Chemother 54:934-6. 2010
  2. ncbi Constrained patterns of covariation and clustering of HIV-1 non-nucleoside reverse transcriptase inhibitor resistance mutations
    Elizabeth C Reuman
    Division of Infectious Diseases, Department of Medicine, Stanford University, 300 Pasteur Drive, Grant S 146, Stanford, CA 94305, USA
    J Antimicrob Chemother 65:1477-85. 2010
  3. ncbi Low-level persistence of drug resistance mutations in hepatitis B virus-infected subjects with a past history of Lamivudine treatment
    Severine Margeridon-Thermet
    Department of Medicine, Division of Infectious Diseases, Stanford University, Stanford, California, USA
    Antimicrob Agents Chemother 57:343-9. 2013
  4. ncbi A classification model for G-to-A hypermutation in hepatitis B virus ultra-deep pyrosequencing reads
    Elizabeth C Reuman
    Department of Medicine, Division of Infectious Diseases, Stanford University, Stanford, CA 94305, USA
    Bioinformatics 26:2929-32. 2010

Collaborators

Detail Information

Publications4

  1. ncbi Panel of prototypical raltegravir-resistant infectious molecular clones in a novel integrase-deleted cloning vector
    Elizabeth C Reuman
    Department of Medicine, Stanford University School of Medicine, Division of Infectious Diseases, 300 Pasteur Drive, Grant Building, Room S 146, Stanford, CA 94305, USA
    Antimicrob Agents Chemother 54:934-6. 2010
    ..Investigational integrase inhibitors with activity against these clones are likely to retain activity against the most clinically relevant raltegravir-resistant variants...
  2. ncbi Constrained patterns of covariation and clustering of HIV-1 non-nucleoside reverse transcriptase inhibitor resistance mutations
    Elizabeth C Reuman
    Division of Infectious Diseases, Department of Medicine, Stanford University, 300 Pasteur Drive, Grant S 146, Stanford, CA 94305, USA
    J Antimicrob Chemother 65:1477-85. 2010
    ....
  3. ncbi Low-level persistence of drug resistance mutations in hepatitis B virus-infected subjects with a past history of Lamivudine treatment
    Severine Margeridon-Thermet
    Department of Medicine, Division of Infectious Diseases, Stanford University, Stanford, California, USA
    Antimicrob Agents Chemother 57:343-9. 2013
    ..001). The likelihood of detecting a LAM resistance mutation was significantly increased using UDPS compared to Sanger sequencing and was inversely associated with the time since LAM discontinuation...
  4. ncbi A classification model for G-to-A hypermutation in hepatitis B virus ultra-deep pyrosequencing reads
    Elizabeth C Reuman
    Department of Medicine, Division of Infectious Diseases, Stanford University, Stanford, CA 94305, USA
    Bioinformatics 26:2929-32. 2010
    ....